本报告导读:CM310 近日获批CRSwNP 适应症,获批进度超预期,鼻窦炎独家适应症有望带动收入增长,2025 年CM310 销售收入有望超5 亿元。投资要点:维持“增持” 评级。维持2024-2026 年预测收入1.56/5.26/14.41 亿元,维持“增持”评级。CM310 成为国内首款CRSwNP 生物药,获批进度超预期。CM310的慢性鼻窦炎伴鼻息肉(CRSwNP)适应症于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.